Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis (Q47203093)

11 January 2018

title

Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis (English)

1 reference

11 January 2018

0 references

1 reference

Eugene Tan

1

1 reference

11 January 2018

Christopher Baker

series ordinal

2

1 reference

11 January 2018

Peter Foley

series ordinal

3

1 reference

11 January 2018

publication date

1 November 2013

1 reference

11 January 2018

Australasian Journal of Dermatology

published in

1 reference

11 January 2018

volume

54

1 reference

11 January 2018

page(s)

259-263

1 reference

11 January 2018

issue

4

1 reference

11 January 2018

Incidence and risk factors for psoriasis in the general population

cites work

1 reference

Epidemiology of psoriasis

21 January 2018

1 reference

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality.

21 January 2018

1 reference

AJC editor's consensus: psoriasis and coronary artery disease.

21 January 2018

1 reference

Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses

21 January 2018

1 reference

Psoriasis: a possible risk factor for development of coronary artery calcification.

21 January 2018

1 reference

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

21 January 2018

1 reference

Weight gain with tumour necrosis factor-alpha inhibitors.

21 January 2018

1 reference

Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study

21 January 2018

1 reference

Body weight increment in patients treated with infliximab for plaque psoriasis.

21 January 2018

1 reference

Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

21 January 2018

1 reference

Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease

21 January 2018

1 reference

Cachexia in rheumatoid arthritis

21 January 2018

1 reference

Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody

21 January 2018

1 reference

The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis.

21 January 2018

1 reference

Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases

21 January 2018

1 reference

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/AJD.12044

1 reference

11 January 2018

PubMed ID

24164178

1 reference

11 January 2018